Issues related to targeted delivery of proteins and peptides

AAPS Journal

Volumn 8, Issue 3, 2006, Pages

  Lu, Yingjuan ^a   Yang, Jun ^b   Sega, Emanuela ^b  

^a Endocyte Inc   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Cancer therapy; Peptide therapeutics; Protein therapeutics; Targeted delivery

Indexed keywords

ANTICOAGULANT AGENT; BACTERIAL TOXIN; BLOOD CLOTTING FACTOR; CETUXIMAB; CYTOKINE; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; GELONIN; GEMTUZUMAB OZOGAMICIN; GONADORELIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HORMONE; IBRITUMOMAB TIUXETAN; INTERLEUKIN 2; LUTEINIZING HORMONE; MONOCLONAL ANTIBODY; PEPTIDE DERIVATIVE; PLANT TOXIN; PROTEIN DERIVATIVE; PSEUDOMONAS EXOTOXIN; RICIN; RITUXIMAB; SOMATOSTATIN; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; BRAIN CANCER; CANCER THERAPY; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG SCREENING; DRUG TARGETING; GENOMICS; HAIRY CELL LEUKEMIA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MELANOMA; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PHYSICAL CHEMISTRY; PROTEIN STABILITY; PROTEOMICS; REVIEW; TUMOR LOCALIZATION;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PEPTIDES; PROTEINS;

EID: 33746644192     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080355     Document Type: Review

References (110)

1. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2:347-360.
2. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002;2:83-90.
3. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev. 2001;46:169-185.
4. Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides. 1999;20:1247-1262.
5. Eklund JW, Kuzel TM. Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther. 2005;5:33-38.
6. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol. 2005;54:11-29.
7. Hertler AA, Frankel AE. Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol. 1989;7:1932-1942.
8. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000;18:1622-1636.
9. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241-247.
10. Sampson JH, Akabani G, Archer GE, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003;65:27-35.
11. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003;65:3-13.
12. Leamon CP, Pastan I, Low PS. Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. J Biol Chem. 1993;268:24847-24854.
13. Leamon CP, Low PS. Selective targeting of malignant cells with cytotoxin-folate conjugates. J Drug Target. 1994;2:101-112.
14. Atkinson SF, Bettinger T, Seymour LW, et al. Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells. J Biol Chem. 2001;276:27930-27935.
15. Frankel AE, Powell BL, Hall PD, et al. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res. 2002;8:1004-1013.
16. Bagshawe KD, Sharma SK, Begent RH. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin Biol Ther. 2004;4:1777-1789.
17. Francis RJ, Sharma SK, Springer C, et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer. 2002;87:600-607.
18. de Graaf M, Boven E, Oosterhoff D, et al. A fully human anti-EpCAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. Br J Cancer. 2002;86:811-818.
19. Spooner RA, Friedlos F, Maycroft K, et al. A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs. Br J Cancer. 2003;88:1622-1630.
20. Lu JY, Lowe DA, Kennedy MD, Low PS. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J Drug Target. 1999;7:43-53.
21. Robinson MA, Charlton ST, Garnier P, et al. LEAPT: lectin-directed enzyme-activated prodrug therapy. Proc Natl Acad Sci USA. 2004;101:14527-14532.
22. Sondel PM, Hank JA, Gan J, et al. Preclinical and clinical development of immunocytokines. Curr Opin Investig Drugs. 2003;4:696-700.
23. Connor JP, Felder M, Hank J, et al. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J Immunother. 2004;27:211-219.
24. Gillies SD, Lan Y, Williams S, et al. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood. 2005;105:3972-3978.
25. Melani C, Figini M, Nicosia D, et al. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res. 1998;58:4146-4154.
26. Metelitsa LS, Gillies SD, Super M, et al. Antidisialoganglioside/ granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood. 2002;99:4166-4173.
27. Lyu MA, Rosenblum MG. The immunocytokine scFv23/TNF sensitizes HER-2/ neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1. Mol Cancer Ther. 2005;4:1205-1213.
28. Notter M, Willinger T, Erben U, Thiel E. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Blood. 2001;97:3138-3145.
29. Patten PA, Schellekens H. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. Dev Biol (Basel). 2003;112:81-97.
30. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. 2004;21:897-903.
31. Kolkman JA, Stemmer WP. Directed evolution of proteins by exon shuffling. Nat Biotechnol. 2001;19:423-428.
32. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24:1720-1740. Discussion 1719.
33. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev. 2003;55:1261-1277.
34. Deen WM, Lazzara MJ, Myers BD. Structural determinants of glomerular permeability. Am J Physiol Renal Physiol. 2001;281:F579-F596.
35. Nishida K, Mihara K, Takino T, et al. Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharm Res. 1991;8:437-444.
36. Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev. 1995;75:591-609.
37. Landers KA, Burger MJ, Tebay MA, et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 2005;114:950-956.
38. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
39. Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther. 1998;286:1020-1025.
40. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002;54: 675-693.
41. Mastrobattista E, Crommelin DJ, Wilschut J, Storm G. Targeted liposomes for delivery of protein-based drugs into the cytoplasm of tumor cells. J Liposome Res. 2002;12:57-65.
42. Becker A, Hessenius C, Licha K, et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol. 2001;19:327-331.
43. Langer M, Beck-Sickinger AG. Peptides as carrier for tumor diagnosis and treatment. Curr Med Chem Anticancer Agents. 2001;1:71-93.
44. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
45. Ma J, Pulfer S, Li S, et al. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001;61:5491-5498.
46. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685-693.
47. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
48. Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther. 2004;3:1493-1501.
49. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest. 2002;110:475-482.
50. Curnis F, Gasparri A, Sacchi A, et al. Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res. 2004;64:565-571.
51. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res. 1989;49:5656-5663.
52. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992;52:5144-5153.
53. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61:4750-4755.
54. Langmuir VK, Mendonca HL, Woo DV. Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids. Cancer Res. 1992;52:4728-4734.
55. Saga T, Neumann RD, Heya T, et al. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci USA. 1995;92:8999-9003.
56. Fracasso G, Colombatti M. Effect of therapeutic macromolecules in spheroids. Crit Rev Oncol Hematol. 2000;36:159-178.
57. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003;63:1288-1296.
58. Le Roy C, Wrana JL. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 2005;6: 112-126.
59. Leamon CP, Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci USA. 1991;88:5572-5576.
60. Wellhoner HH, Jr, Neville DM, Jr, Srinivasachar K, Erdmann G. Uptake and concentration of bioactive macromolecules by K562 cells via the transferrin cycle utilizing an acid-labile transferrin conjugate. J Biol Chem. 1991;266:4309-4314.
61. El-Sayed ME, Hoffman AS, Stayton PS. Smart polymeric carriers for enhanced intracellular delivery of therapeutic macromolecules. Expert Opin Biol Ther. 2005;5:23-32.
62. Mastrobattista E, Koning GA, van Bloois L, et al. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem. 2002;277:27135-27143.
63. Kakudo T, Chaki S, Futaki S, et al. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry. 2004;43:5618-5628.
64. Berg K, Selbo PK, Prasmickaite L, et al. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res. 1999;59:1180-1183.
65. Selbo PK, Sivam G, Fodstad O, et al. In vivo documentation of photochemical internalization, a novel approach to site specific cancer therapy. Int J Cancer. 2001;92:761-766.
66. Selbo PK, Sivam G, Fodstad O, et al. Photochemical internalisation increases the cytotoxic effect of the immunotoxin MOC31-gelonin. Int J Cancer. 2000;87:853-859.
67. Hogset A, Prasmickaite L, Selbo PK, et al. Photochemical internalisation in drug and gene delivery. Adv Drug Deliv Rev. 2004;56:95-115.
68. Brem S. Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control. 1999;6:436-458.
69. Adessi C, Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem. 2002;9:963-978.
70. Binetruy-Tournaire R, Demangel C, Malavaud B, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 2000;19:1525-1533.
71. Reiher FK, Volpert OV, Jimenez B, et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer. 2002;98:682-689.
72. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y). 1995;13:265-270.
73. Kumar CC, Malkowski M, Yin Z, et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res. 2001;61:2232-2238.
74. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000;60:722-727.
75. Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 1999;17:768-774.
76. Laakkonen P, Akerman ME, Biliran H, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci USA. 2004;101:9381-9386.
77. Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers. 2002;66:161-183.
78. Kanashiro CA, Schally AV, Groot K, et al. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proc Natl Acad Sci USA. 2003;100:15836-15841.
79. Stangelberger A, Schally AV, Varga JL, et al. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clin Cancer Res. 2005;11:49-57.
80. Schally AV, Comaru-Schally AM, Plonowski A, et al. Peptide analogs in the therapy of prostate cancer. Prostate. 2000;45:158-166.
81. Colombo G, Curnis F, De Mori GM, et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem. 2002;277:47891-47897.
82. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-380.
83. Chen Y, Xu X, Hong S, et al. RGD-Tachyplesin inhibits tumor growth. Cancer Res. 2001;61:2434-2438.
84. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999;5:1032-1038.
85. de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging. 2003;30:463-469.
86. Scopinaro F, De Vincentis G, Corazziari E, et al. Detection of colon cancer with 99mTc-labeled bombesin derivative (99mTc-leu13-BN1). Cancer Biother Radiopharm. 2004;19:245-252.
87. Varvarigou A, Bouziotis P, Zikos C, et al. Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother Radiopharm. 2004;19:219-229.
88. Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci. 2003;72:2305-2320.
89. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab. 2004;15:300-310.
90. Leuschner C, Enright FM, Gawronska-Kozak B, Hansel W. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors. Prostate. 2003;56:239-249.
91. Gawronska B, Leuschner C, Enright FM, Hansel W. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo. Gynecol Oncol. 2002;85:45-52.
92. Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000;18:1185-1190.
93. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31:1133-1140.
94. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
95. Hamel E. Interactions of antimitotic peptides and depsipeptides with tubulin. Biopolymers. 2002;66:142-160.
96. Edelman MJ, Gandara DR, Hausner P, et al. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2003;39:197-199.
97. Marks RS, Graham DL, Sloan JA, et al. A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer. Am J Clin Oncol. 2003;26:336-337.
98. Law CL, Cerveny CG, Gordon KA, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res. 2004;10:7842-7851.
99. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778-784.
100. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458-1465.
101. Bhaskar V, Law DA, Ibsen E, et al. E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res. 2003;63:6387-6394.
102. Afar DE, Bhaskar V, Ibsen E, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther. 2004;3:921-932.
103. Low PS, Antony AC. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev. 2004;56:1055-1058.
104. Paulos CM, Reddy JA, Leamon CP, et al. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol. 2004;66: 1406-1414.
105. Lu Y, Sega E, Low PS. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. Int J Cancer. 2005;116:710-719.
106. Shinoda T, Takagi A, Maeda A, et al. In vivo fate of folate-BSA in non-tumor- and tumor-bearing mice. J Pharm Sci. 1998;87: 1521-1526.
107. Ward CM, Acheson N, Seymour LW. Folic acid targeting of protein conjugates into ascites tumour cells from ovarian cancer patients. J Drug Target. 2000;8:119-123.
108. Roy EJ, Gawlick U, Orr BA, Kranz DM. Folate-mediated targeting of T cells to tumors. Adv Drug Deliv Rev. 2004;56:1219-1231.
109. Kennedy MD, Jallad KN, Thompson DH, et al. Optical imaging of metastatic tumors using a folate-targeted fluorescent probe. J Biomed Opt. 2003;8:636-641.
110. Lu Y, Low PS. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother. 2002;51:153-162.